A novel triple therapy shows promising signs of efficacy in localised lung cancer
The MATISSE study, presented by Professor Fabrice Barlesi, CEO of Gustave Roussy, during a plenary session on clinical trials at the AACR congress, evaluated the addition of a new molecule to the therapeutically validated combination already used for certain patients with non-small cell lung cancer. This novel triple therapy has demonstrated initial promising clinical effects.
The Fifth Transatlantic Exchange in Oncology, A Collaborative Approach to Delivering Excellence With the exclusive participation of Dana-Farber Cancer Institute and Gustave Roussy (France)
the Fifth Transatlantic Exchange in Oncology, is focusing this year on Transatlantic Innovations in Cancer Drug Research.